Pangaea Oncology (Spain) Market Value

PANG Stock  EUR 1.69  0.04  2.31%   
Pangaea Oncology's market value is the price at which a share of Pangaea Oncology trades on a public exchange. It measures the collective expectations of Pangaea Oncology SA investors about its performance. Pangaea Oncology is trading at 1.69 as of the 17th of January 2026, a 2.31% down since the beginning of the trading day. The stock's open price was 1.73.
With this module, you can estimate the performance of a buy and hold strategy of Pangaea Oncology SA and determine expected loss or profit from investing in Pangaea Oncology over a given investment horizon. Check out Pangaea Oncology Correlation, Pangaea Oncology Volatility and Pangaea Oncology Alpha and Beta module to complement your research on Pangaea Oncology.
Symbol

Please note, there is a significant difference between Pangaea Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pangaea Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pangaea Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Pangaea Oncology 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pangaea Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pangaea Oncology.
0.00
12/18/2025
No Change 0.00  0.0 
In 30 days
01/17/2026
0.00
If you would invest  0.00  in Pangaea Oncology on December 18, 2025 and sell it all today you would earn a total of 0.00 from holding Pangaea Oncology SA or generate 0.0% return on investment in Pangaea Oncology over 30 days. Pangaea Oncology is related to or competes with Biotechnology Assets, Elaia Investment, Bankinter, Caixabank, Media Investment, and International Consolidated. Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients, and pharmaceutical ... More

Pangaea Oncology Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pangaea Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pangaea Oncology SA upside and downside potential and time the market with a certain degree of confidence.

Pangaea Oncology Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Pangaea Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pangaea Oncology's standard deviation. In reality, there are many statistical measures that can use Pangaea Oncology historical prices to predict the future Pangaea Oncology's volatility.
Hype
Prediction
LowEstimatedHigh
0.351.693.03
Details
Intrinsic
Valuation
LowRealHigh
0.351.693.04
Details

Pangaea Oncology Backtested Returns

Pangaea Oncology maintains Sharpe Ratio (i.e., Efficiency) of close to zero, which implies the firm had a close to zero % return per unit of risk over the last 3 months. Pangaea Oncology exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Pangaea Oncology's Variance of 1.68, risk adjusted performance of 0.0043, and Coefficient Of Variation of (192,695) to confirm the risk estimate we provide. The company holds a Beta of 0.34, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pangaea Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pangaea Oncology is expected to be smaller as well. At this point, Pangaea Oncology has a negative expected return of -7.0E-4%. Please make sure to check Pangaea Oncology's treynor ratio, skewness, and the relationship between the total risk alpha and potential upside , to decide if Pangaea Oncology performance from the past will be repeated at some point in the near future.

Auto-correlation

    
  0.34  

Below average predictability

Pangaea Oncology SA has below average predictability. Overlapping area represents the amount of predictability between Pangaea Oncology time series from 18th of December 2025 to 2nd of January 2026 and 2nd of January 2026 to 17th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pangaea Oncology price movement. The serial correlation of 0.34 indicates that nearly 34.0% of current Pangaea Oncology price fluctuation can be explain by its past prices.
Correlation Coefficient0.34
Spearman Rank Test0.15
Residual Average0.0
Price Variance0.0

Pangaea Oncology lagged returns against current returns

Autocorrelation, which is Pangaea Oncology stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Pangaea Oncology's stock expected returns. We can calculate the autocorrelation of Pangaea Oncology returns to help us make a trade decision. For example, suppose you find that Pangaea Oncology has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
   Current and Lagged Values   
       Timeline  

Pangaea Oncology regressed lagged prices vs. current prices

Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Pangaea Oncology stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Pangaea Oncology stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Pangaea Oncology stock over time.
   Current vs Lagged Prices   
       Timeline  

Pangaea Oncology Lagged Returns

When evaluating Pangaea Oncology's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Pangaea Oncology stock have on its future price. Pangaea Oncology autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Pangaea Oncology autocorrelation shows the relationship between Pangaea Oncology stock current value and its past values and can show if there is a momentum factor associated with investing in Pangaea Oncology SA.
   Regressed Prices   
       Timeline  

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Pangaea Stock

Pangaea Oncology financial ratios help investors to determine whether Pangaea Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pangaea with respect to the benefits of owning Pangaea Oncology security.